Prior systemic therapy targeting PD-1: PD-L1 axis. 
Patients who are curable by conventional multidisciplinary management. 
Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol. 
Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation < 2 weeks prior to screening or who have not recovered adequately from side effects of such therapy. 
Patients who have active infections requiring therapy. 
Patients that are known to be positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (HBsAg reactive), or Hepatitis C (HCV RNA [qualitative] is detected); patients with negative Hepatitis C antibody testing may not need RNA testing. 
Patients that have a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial. 
Patients who received systemic anti-cancer treatment prior to the first dose of study drug within the following time frames: 
Patients with active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy would be exception to this rule. Patients that require inhaled steroids or local steroid injections would not be excluded from the study. Patients with hypothyroidism not from autoimmune disease that is stable on hormone replacement will not be excluded from the study. 
Women who are pregnant or nursing/breastfeeding. 
Known hypersensitivity to pembrolizumab or another mAb. 
Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis. 
Patients with untreated central nervous system disease. Patients with controlled treated CNS lesions who have undergone surgery or stereotactic radiosurgery and stable for 4 weeks are eligible. 
Inability to comply with protocol required procedures. 
Patients with medical conditions that require chronic systemic corticosteroid therapy or require any other form of immunosuppressive medication. However, patients using physiologic replacement doses of hydrocortisone, or its equivalent, will be considered eligible for this study: up to 20 mg hydrocortisone (or 5 mg of prednisone) in the morning and 10 mg hydrocortisone (or 2.5 mg prednisone) in the evening. 
Patients with the risk factors for bowel obstruction or bowel perforation (examples include but not limited to a history of acute diverticulitis, intra-abdominal abscess, abdominal carcinomatosis). 
Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment.       
    

NCT02301039_exc_T1
Procedure
systemic therapy targeting PD-1: PD-L1 axis
NCT02301039_exc_T2
Procedure
conventional multidisciplinary management
NCT02301039_exc_T3
Qualifier
curable
NCT02301039_exc_T5
Condition
medical disease
NCT02301039_exc_T7
Temporal
concurrent
NCT02301039_exc_T8
Qualifier
uncontrolled
NCT02301039_exc_T9
Qualifier
severe
NCT02301039_exc_T10
Scope
severe and/or uncontrolled
NCT02301039_exc_T13
Procedure
wide field radiotherapy
NCT02301039_exc_T14
Temporal
≤ 4 weeks
NCT02301039_exc_T15
Procedure
limited field radiation for palliation
NCT02301039_exc_T16
Temporal
< 2 weeks prior to screening
NCT02301039_exc_T17
Reference_point
screening
NCT02301039_exc_T18
Condition
recovered
NCT02301039_exc_T19
Qualifier
adequately
NCT02301039_exc_T20
Negation
not
NCT02301039_exc_T21
Condition
side effects of such therapy
NCT02301039_exc_T23
Procedure
such therapy
NCT02301039_exc_T24
Condition
infections
NCT02301039_exc_T25
Procedure
therapy
NCT02301039_exc_T26
Qualifier
requiring therapy
NCT02301039_exc_T27
Measurement
Human Immunodeficiency Virus (HIV)
NCT02301039_exc_T28
Value
positive
NCT02301039_exc_T29
Qualifier
HIV 1/2 antibodies
NCT02301039_exc_T30
Condition
active Hepatitis B
NCT02301039_exc_T31
Measurement
HBsAg
NCT02301039_exc_T32
Value
reactive
NCT02301039_exc_T33
Condition
Hepatitis C
NCT02301039_exc_T34
Measurement
HCV RNA [qualitative]
NCT02301039_exc_T35
Value
detected
NCT02301039_exc_T36
Measurement
Hepatitis C antibody
NCT02301039_exc_T37
Value
negative
NCT02301039_exc_T40
Condition
psychiatric disorder
NCT02301039_exc_T41
Condition
substance abuse disorder
NCT02301039_exc_T43
Procedure
systemic anti-cancer treatment
NCT02301039_exc_T44
Temporal
prior to the first dose of study drug
NCT02301039_exc_T45
Reference_point
the first dose of study drug
NCT02301039_exc_T47
Condition
autoimmune disease
NCT02301039_exc_T48
Temporal
active
NCT02301039_exc_T49
Condition
autoimmune disease
NCT02301039_exc_T50
Observation
history
NCT02301039_exc_T51
Condition
syndrome that requires systemic steroids
NCT02301039_exc_T52
Drug
systemic steroids
NCT02301039_exc_T54
Drug
immunosuppressive agents
NCT02301039_exc_T55
Condition
syndrome that requires immunosuppressive agents
NCT02301039_exc_T56
Condition
childhood asthma
NCT02301039_exc_T57
Qualifier
resolved
NCT02301039_exc_T58
Condition
vitiligo
NCT02301039_exc_T59
Condition
atopy
NCT02301039_exc_T63
Condition
hypothyroidism
NCT02301039_exc_T64
Condition
autoimmune disease
NCT02301039_exc_T65
Negation
not
NCT02301039_exc_T66
Qualifier
stable on hormone replacement
NCT02301039_exc_T67
Procedure
hormone replacement
NCT02301039_exc_T70
Person
Women
NCT02301039_exc_T71
Condition
pregnant
NCT02301039_exc_T72
Condition
nursing
NCT02301039_exc_T73
Observation
breastfeeding
NCT02301039_exc_T74
Condition
hypersensitivity to pembrolizumab
NCT02301039_exc_T75
Drug
pembrolizumab
NCT02301039_exc_T76
Condition
hypersensitivity to mAb
NCT02301039_exc_T77
Drug
mAb
NCT02301039_exc_T78
Drug
steroids
NCT02301039_exc_T79
Condition
pneumonitis
NCT02301039_exc_T80
Temporal
current
NCT02301039_exc_T81
Condition
pneumonitis
NCT02301039_exc_T82
Observation
history
NCT02301039_exc_T83
Qualifier
required steroids
NCT02301039_exc_T84
Condition
central nervous system disease
NCT02301039_exc_T86
Qualifier
untreated
NCT02301039_exc_T87
Condition
CNS lesions
NCT02301039_exc_T88
Procedure
surgery
NCT02301039_exc_T89
Procedure
stereotactic radiosurgery
NCT02301039_exc_T90
Temporal
for 4 weeks
NCT02301039_exc_T91
Qualifier
stable
NCT02301039_exc_T92
Scope
surgery or stereotactic radiosurgery
NCT02301039_exc_T93
Qualifier
controlled
NCT02301039_exc_T94
Qualifier
treated
NCT02301039_exc_T95
Condition
Inability to comply with protocol required procedures.
NCT02301039_exc_T99
Condition
medical conditions
NCT02301039_exc_T100
Procedure
systemic corticosteroid therapy
NCT02301039_exc_T101
Temporal
chronic
NCT02301039_exc_T102
Drug
immunosuppressive medication
NCT02301039_exc_T104
Qualifier
require chronic systemic corticosteroid therapy
NCT02301039_exc_T105
Qualifier
require immunosuppressive medication
NCT02301039_exc_T106
Scope
require chronic systemic corticosteroid therapy or require any other form of immunosuppressive medication
NCT02301039_exc_T107
Multiplier
physiologic replacement doses
NCT02301039_exc_T108
Drug
hydrocortisone
NCT02301039_exc_T109
Drug
hydrocortisone
NCT02301039_exc_T110
Multiplier
up to 20 mg
NCT02301039_exc_T111
Drug
prednisone
NCT02301039_exc_T112
Multiplier
5 mg
NCT02301039_exc_T113
Drug
hydrocortisone
NCT02301039_exc_T114
Multiplier
10 mg
NCT02301039_exc_T115
Drug
prednisone
NCT02301039_exc_T116
Multiplier
2.5 mg
NCT02301039_exc_T117
Multiplier
in the morning
NCT02301039_exc_T118
Multiplier
in the evening
NCT02301039_exc_T119
Scope
up to 20 mg hydrocortisone (or 5 mg of prednisone) in the morning and 10 mg hydrocortisone (or 2.5 mg prednisone) in the evening
NCT02301039_exc_T120
Scope
physiologic replacement doses of hydrocortisone
NCT02301039_exc_T121
Condition
bowel obstruction
NCT02301039_exc_T122
Condition
bowel perforation
NCT02301039_exc_T123
Condition
risk factors for bowel obstruction
NCT02301039_exc_T124
Condition
risk factors for bowel perforation
NCT02301039_exc_T125
Observation
history
NCT02301039_exc_T126
Condition
acute diverticulitis
NCT02301039_exc_T127
Condition
intra-abdominal abscess
NCT02301039_exc_T128
Condition
abdominal carcinomatosis
NCT02301039_exc_T129
Scope
acute diverticulitis, intra-abdominal abscess, abdominal carcinomatosis
NCT02301039_exc_T130
Scope
risk factors for bowel obstruction or bowel perforation
NCT02301039_exc_T131
Drug
live vaccine
NCT02301039_exc_T132
Temporal
within 30 days prior to the first dose of trial treatment
NCT02301039_exc_T133
Reference_point
the first dose of trial treatment